Qi Jin

Qi Jin

Auto-generated profile, based on publicly available information

Qi Jin

Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Science Advances
Verified
Journal Article
Open access
CHCuijuan Han
Cuijuan Han
AKAlireza Khodadadi-Jamayran
Alireza Khodadadi-Jamayran
ALAdam H. Lorch
Adam H. Lorch
QJQi Jin
Qi Jin
Valentina SerafinValentina Serafin
Valentina Serafin
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
The production of noncanonical mRNA transcripts is associated with cell transformation. Driven by our previous findings on the sensitivity of T cell acute lymphoblastic leukemia (T-ALL) cells to SF3B1 inhibitors, we identified that SF3B1 inhibition blocks T-ALL growth in vivo with no notable associated toxicity. We also revealed protein stabilization of the U2 complex component SF3B1 via deubiquitination. Our studies showed that SF3B1 inhibition perturbs exon skipping, leading to nonsense-mediated decay and diminished levels of DNA damage response–related transcripts, such as the serine/threonine kinase CHEK2 , and impaired DNA damage response. We also identified that SF3B1 inhibition leads to a general decrease in R-loop formation. We further demonstrate that clinically used SF3B1 inhibitors synergize with CHEK2 inhibitors and chemotherapeutic drugs to block leukemia growth. Our study provides the proof of principle for posttranslational regulation of splicing components and associated roles and therapeutic implications for the U2 complex in T cell leukemia.

9 December 2022 in Science Advances
Verified
Journal Article
Open access
QJQi Jin
Qi Jin
BDBlanca Gutierrez Diaz
Blanca Gutierrez Diaz
TPTim Pieters
Tim Pieters
YZYalu Zhou
Yalu Zhou
SNSonali Narang
Sonali Narang
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in T cell acute lymphoblastic leukemia (T-ALL). We observed that the ubiquitin-specific protease 11 (USP11) is highly expressed and associates with poor prognosis in T-ALL. USP11 ablation inhibits leukemia progression in vivo, sparing normal hematopoiesis. USP11 forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell–specific protein-tyrosine kinase (LCK) and enhance its activity. Impairment of LCK activity leads to increased glucocorticoid receptor (GR) expression and glucocorticoids sensitivity. Genetic knockout of USP7 improved the antileukemic efficacy of glucocorticoids in vivo. The transcriptional activation of GR target genes is orchestrated by the deubiquitinase activity and mediated via an increase in enhancer-promoter interaction intensity. Our data unveil how dysregulated deubiquitination controls leukemia survival and drug resistance, suggesting previously unidentified therapeutic combinations toward targeting leukemia.

1 September 2003 in Experimental Hematology
Verified
Journal Article
Closed access
AGAnnie C Le Guern
Annie C Le Guern
MGMaria A Giovino
Maria A Giovino
MAMasahiro Abe
Masahiro Abe
PTPierre R Theodore
Pierre R Theodore
JQJin Qi
Jin Qi
YYYongguang Yang
Yongguang Yang

5 December 2024 in Blood
Verified
Journal Article
Open access
QJQi Jin
Qi Jin
EHEthan Harris
Ethan Harris
JMJacquelyn A. Myers
Jacquelyn A. Myers
RMRashid Mehmood
Rashid Mehmood
ACAnitria Cotton
Anitria Cotton
JCJohn D. Crispino
John D. Crispino
There are only a few options for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), thus, this is a major area of unmet medical need. In this study, we reveal that the inclusion of a poison exon in RBM39, which could be induced by both CDK9 or CDK9 independent cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases (CMGC) kinase inhibition, is recognized by the nonsense-mediated messenger RNA decay pathway for degradation. Targeting this poison exon in RBM39 with CMGC inhibitors led to protein downregulation and the inhibition of ALL growth, particularly in relapsed/refractory B-ALL. Mechanistically, disruption of cotranscriptional splicing by the inhibition of CMGC kinases, including DYRK1A, or inhibition of CDK9, which phosphorylate the C-terminal domain of RNA polymerase II (Pol II), led to alteration in the SF3B1 and Pol II association. Disruption of SF3B1 and the transcriptional elongation complex altered Pol II pausing, which promoted the inclusion of a poison exon in RBM39. Moreover, RBM39 ablation suppressed the growth of human B-ALL, and targeting RBM39 with sulfonamides, which degrade RBM39 protein, showed strong antitumor activity in preclinical models. Our data reveal that relapsed/refractory B-ALL is susceptible to pharmacologic and genetic inhibition of RBM39 and provide 2 potential strategies to target this axis.

1 January 2008 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
ZXZhaoHui Xiong
ZhaoHui Xiong
CWCanDong Wei
CanDong Wei
JYJian Yang
Jian Yang
JPJunping Peng
Junping Peng
XXXingYe Xu
XingYe Xu
QJQi Jin
Qi Jin